TFCP2 Antibody

Basic Research Questions

• What is TFCP2 and why are TFCP2 antibodies important in research?

TFCP2 (Transcription Factor Cellular Promoter 2, also known as LSF or SEF) is a ubiquitously expressed transcription factor that was originally discovered to bind and activate the alpha-globin promoter in erythroid cells . It belongs to a subfamily of Grainyhead-like (GRHL) transcription factors and plays crucial roles in multiple biological processes.

TFCP2 antibodies are essential tools for investigating:

• Transcriptional regulation mechanisms

• Cancer progression and metastasis

• Cell senescence pathways

• Protein-protein interactions in signaling pathways

Research has implicated TFCP2 in hepatocellular carcinoma, melanoma, pancreatic cancer, breast cancer, and various other malignancies, making these antibodies critical for cancer biology research .

• What applications are TFCP2 antibodies commonly used for?

TFCP2 antibodies are utilized in multiple experimental techniques:

Most validated TFCP2 antibodies demonstrate reactivity with human, mouse, and rat samples, with some showing cross-reactivity to other species .

• How do I validate a TFCP2 antibody for my research?

Comprehensive validation of TFCP2 antibodies should include:

• Specificity verification:

  • Use TFCP2 knockout or knockdown cells as negative controls

  • Western blot should show a single band at the expected molecular weight (~57 kDa calculated, often observed at 65-66 kDa)

  • Peptide competition assay to confirm specificity

• Validation across applications:

  • If using for multiple applications (e.g., WB and IHC), validate separately for each

  • Verify subcellular localization matches known nuclear distribution of TFCP2

• Cross-reactivity assessment:

  • If using across species, confirm reactivity in each target species

  • Sequence alignment analysis can predict cross-reactivity based on epitope conservation

• Functional validation:

  • Use the antibody in IP followed by mass spectrometry to confirm it pulls down TFCP2 and known interacting partners

  • Verify detection in samples with known TFCP2 expression levels

• What are the best practices for sample preparation when using TFCP2 antibodies?

Optimal sample preparation is critical for successful TFCP2 detection:

For Western Blotting:

• Nuclear extraction is preferred as TFCP2 is primarily a nuclear protein

• Use protease inhibitors to prevent degradation

• Include phosphatase inhibitors if studying TFCP2 phosphorylation states

• Optimize lysis buffer conditions (RIPA or NP-40 buffers are commonly effective)

• For pancreatic or liver tissue samples, additional purification steps may be needed to remove interfering substances

For IHC/IF:

• Fixation: 4% paraformaldehyde typically preserves TFCP2 antigenicity

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective

• Blocking: 5% BSA or normal serum from the secondary antibody host species

• Primary antibody incubation: Overnight at 4°C for optimal signal-to-noise ratio

• Include positive controls (spleen or liver tissue) which show consistent TFCP2 expression

• How should TFCP2 antibodies be stored and handled?

Proper storage and handling are essential for maintaining antibody performance:

Storage conditions:

• Store at -20°C in small aliquots to prevent freeze-thaw cycles

• For long-term storage, -80°C is recommended

• Short-term storage (up to 1 week) at 2-8°C is acceptable

Buffer composition:

• Typical storage buffers contain PBS with 0.02-0.09% sodium azide and 50% glycerol at pH 7.3

• Some formulations include stabilizers like BSA (0.1-1%)

Handling guidelines:

• Avoid repeated freeze-thaw cycles (more than 3-5 cycles can degrade activity)

• Centrifuge briefly before opening to collect solution at the bottom

• Use clean pipette tips to prevent contamination

• For diluted working solutions, prepare fresh or store at 4°C for no more than 2 weeks

Advanced Research Questions

• How can I optimize TFCP2 antibody use for studying its role in transcriptional regulation?

Investigating TFCP2's role as a transcription factor requires specialized approaches:

Chromatin Immunoprecipitation (ChIP) optimization:

• Crosslinking: 1% formaldehyde for 10 minutes typically works well for TFCP2

• Sonication: Optimize to achieve 200-500bp DNA fragments

• Antibody amount: 2-5μg per ChIP reaction is typically sufficient

• Include appropriate controls:

  • IgG negative control

  • Known TFCP2 target genes as positive controls (α-globin, SULF1)

Target gene validation methods:

• Direct binding assessment: Combine ChIP with qPCR to quantify enrichment at suspected binding sites. Research has identified TFCP2 binding sites in multiple gene promoters, including:

  • SULF1 promoter (-803 bp from transcription start site)

  • EGF and TGFα promoters

  • HMGCR promoter (in cooperation with SREBP2)

• Functional validation: Use reporter gene assays with wild-type and mutated TFCP2 binding sites. For example, the nano-luciferase reporter gene assay with the SULF1 promoter showed significant increase in luciferase expression in the absence of TFCP2, confirming negative regulation .

• What are the best approaches for using TFCP2 antibodies in cancer research models?

TFCP2 has been implicated in multiple cancer types, requiring tailored approaches:

For pancreatic cancer research:

• Analyze TFCP2-SREBP2 interaction using co-immunoprecipitation

• Examine cholesterol synthesis pathway components, especially HMGCR

• Assess senescence markers (p16, p21) in relation to TFCP2 expression

• Study β-catenin/TCF signaling activation using reporter assays

For breast cancer (especially TNBC):

• Focus on EMT markers and stemness characteristics

• Assess EGF and TGFα expression levels in relation to TFCP2

• Examine EGFR signaling pathway components

• How can I investigate TFCP2-protein interactions using co-immunoprecipitation approaches?

Optimized co-IP protocols for TFCP2:

Protocol optimization:

• Cell lysis: Use gentle lysis buffers (e.g., 50mM Tris-HCl pH 7.5, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate) with protease inhibitors

• Pre-clearing: Incubate lysates with protein A/G beads to reduce non-specific binding

• Antibody binding: 2-5μg TFCP2 antibody per 1mg protein lysate, incubate overnight at 4°C

• Washing: 3-5 washes with lysis buffer containing reduced detergent concentration

• Elution: Use either low pH buffer or SDS sample buffer depending on downstream applications

Key TFCP2 interaction partners to investigate:

• SREBP2: Co-IP studies have shown TFCP2 interacts with SREBP2 to regulate cholesterol synthesis genes

• β-catenin/TCF4: TFCP2 strengthens this interaction in pancreatic cancer

• YAP1: Forms a complex with TFCP2 to regulate PD-L1 expression in melanoma

Validation approaches:

• Reverse co-IP (using antibodies against interaction partners)

• GST pull-down assays (GST-SREBP2N fusion protein has been shown to pull down endogenous TFCP2)

• Proximity ligation assay for in situ visualization of interactions

• How do I interpret changes in TFCP2 expression in CRISPR knockout models?

When analyzing TFCP2 CRISPR knockout models, consider these methodological aspects:

Verification of knockout efficiency:

• Western blotting using validated antibodies

• Sanger sequencing to confirm genomic edits

• RT-qPCR for mRNA level verification

Phenotypic analysis framework:

• Growth characteristics: TFCP2 knockout in melanoma cells showed slowed growth compared to wild-type cells

• Morphological assessment: Some studies report no morphological changes in TFCP2 knockout cells compared to parental lines

• Functional assays:

  • Cell proliferation (MTT assay, colony formation)

  • Migration and invasion capabilities

  • Anchorage-independent growth in soft agar

Molecular pathway analysis:

• RNA sequencing: TFCP2 knockout in melanoma cells revealed altered expression of multiple enzymes involved in HS assembly, including SULF1

• Protein interaction changes: Assess changes in key interaction partners

• Target gene expression: Measure expression of known TFCP2 targets like SULF1, EGF, TGFα, or HMGCR

Rescue experiments:
For conclusive evidence of TFCP2-specific effects, perform rescue experiments by re-introducing TFCP2 cDNA (consider HA-tagged constructs to distinguish from endogenous protein)

• How can I use TFCP2 antibodies to study its role in different subcellular compartments?

TFCP2 functions in multiple cellular compartments, requiring specialized approaches:

Nuclear localization studies:

• Subcellular fractionation followed by Western blotting

• Immunofluorescence with confocal microscopy

• Co-staining with nuclear markers (DAPI, lamin)

Cytoplasmic functions investigation:

• Proximity-dependent biotinylation (BioID or TurboID) with TFCP2 fusion proteins

• Live-cell imaging with fluorescent-tagged TFCP2

• Super-resolution microscopy for detailed localization patterns

Protocol optimization for immunofluorescence:

• Fixation: 4% paraformaldehyde (10 minutes) preserves nuclear architecture

• Permeabilization: 0.25% Triton X-100 for nuclear antibody access

• Blocking: 5% BSA or normal serum

• Primary antibody: Incubate at 1:100-1:200 dilution overnight at 4°C

• Secondary antibody: Fluorophore-conjugated, species-specific antibodies at 1:500 dilution

• Nuclear counterstain: DAPI or Hoechst at 1:1000 dilution

• How do I analyze contradictory results when using different TFCP2 antibodies?

When facing contradictory results with different TFCP2 antibodies:

Systematic troubleshooting approach:

• Epitope mapping analysis:

  • Different antibodies target different regions of TFCP2

  • N-terminal antibodies (AA 38-87) may detect different forms than C-terminal antibodies

  • Splice variants or post-translational modifications might affect epitope accessibility

• Specificity verification for each antibody:

  • TFCP2 knockout samples as negative controls

  • Peptide competition assays

  • Immunoprecipitation followed by mass spectrometry

• Context-dependent expression considerations:

  • TFCP2 expression can vary by tissue/cell type

  • Expression in spleen tissue is consistently high and can serve as positive control

  • Cancer cells may show altered TFCP2 expression profiles

Data reconciliation strategies:

• Use multiple antibodies targeting different epitopes in parallel

• Employ complementary detection methods (e.g., antibody detection + mRNA analysis)

• Consider species-specific differences when working across model systems

• Document exact experimental conditions for each antibody

• What methodologies are recommended for studying TFCP2 in tumor samples?

Investigating TFCP2 in tumor samples requires specialized approaches:

Tissue preparation optimization:

• Fresh frozen samples yield better protein quality for Western blot and IP

• FFPE samples work well for IHC but may require optimized antigen retrieval

• Consider tissue microarrays for high-throughput analysis across multiple patients

Multi-marker analysis framework:

• For melanoma: Combine TFCP2 with SULF1 and FGF1 staining

• For pancreatic cancer: Co-stain for TFCP2, SREBP2, and HMGCR

• For breast cancer: Analyze TFCP2 alongside EMT markers

Heterogeneity assessment:

• Single-cell approaches to account for tumor heterogeneity

• Spatial analysis of TFCP2 expression within tumor microenvironments

• Compare primary tumors with metastatic lesions (TFCP2 has been implicated in metastasis)